New hope for rare skin Flare-Ups: drug offered to those with no options

NCT ID NCT05239039

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This program in China gave a single infusion of spesolimab to 39 people with a severe skin condition called generalized pustular psoriasis (GPP) during a flare-up. Participants had no other treatment options available. The goal was to control the flare and monitor for side effects over about 4 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

generalized pustular psoriasis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED PUSTULAR PSORIASIS

Contacts and locations

Locations

Beijing Friendship Hospital

Beijing, 100050, China
Dermatology Hospital, Chinese Academy of Medical Sciences

Nanjing, 210000, China
Hangzhou Third People's Hospital

Hangzhou, 310013, China
Shandong Provincial Hospital of Dermatology

Jinan, 250063, China
Shanghai Skin Disease Hospital

Shanghai, 200000, China
Southern Medical University Dermatology Hospital

Guangzhou, 510091, China
The First Hospital of China Medical University

Shenyang, 110001, China
The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, 310009, China
The University of Hong Kong-Shenzhen Hospital

Shenzhen, 518053, China
Tianjin Medical University General Hospital

Tianjin, 30052, China
West China Hospital

Chengdu, 610041, China
Wuhan Union Hospital

Wuhan, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.